Current issue
Archive
Online first
About the Journal
Editorial Office
Editorial Board
Publisher
Editorial Policies
Ethical standards and procedures
Abstracting and indexing
Reviewers
Honorary Reviewers
Subscription
Contact
Most read articles
Instructions for authors
Article processing charge (APC)
Books and Events
Books
Events
EDITORIAL ARTICLE
Neonatal lupus: fighting an unknown enemy?
Online publication date: 2011-06-06
Reumatologia 2011;49(3):149-155
KEYWORDS
ABSTRACT
Neonatal lupus (NL) affects 2% of children of mothers with detectable levels of anti-SSA/Ro and/or anti-SSB/La. Atrio-ventricular heart block, which constitutes the earliest symptom of the disease, is diagnosed between 18 and 24 weeks of gestation and, together with the developing generalized heart disease, is largely responsible for the prognosis. Recent research studies as well as results of randomized clinical trials significantly increased our knowledge about pathogenesis and clinical course of NL as well as possible therapeutic options.
REFERENCES (38)
1.
Salomonsson S, Sonesson SE, Ottosson L, et al. Ro/SSA autoantibodies directly bind cardiomyocytes, disturb calcium homeostasis, and mediate congenital heart block. J Exp Med 2005; 201: 11-17. .
2.
Deng JS, Bair LW Jr, Shen-Schwarz S, et al. Localization of Ro (SS-A) antigen in the cardiac conduction system. Arthritis Rheum 1987; 30: 1232-1238. .
3.
Deng JS, Sontheimer RD, Gilliam JN. Expression of Ro/SS-A antigen in human skin and heart. J Invest Dermatol 1985; 85: 412-416. .
4.
Aranegiu B, Batalla A, Florez A, et al. A case of NLE with cutaneous and cardiac involvement. J Am Acad Dermatol 2011; 2: 137. .
5.
Clowse M. Managing contraception and pregnancy in the rheumatologic diseases. Best Pract Res Clin Rheum 2010; 24: 373-85. .
6.
Smith P, Gordon C. SLE: clinical presentations. Autoimmunity Reviews 2010; 10: 43-45. .
7.
Gordon P, Khamashta MA, Rosenthal E, et al. Anti-52 kDa, anti-60 kDa Ro and anti-La antibody profiles in neonatal lupus. J Rheumatol 2004; 31: 2480-2487. .
8.
Borchers A, Naguwa S, Keen C, Gershwin ME. The implications of autoimmunity and pregnancy. J Autoimmunity 2010; 34: 287-299. .
9.
Buyon JP, Clancy RM. Neonatal lupus. In: Dubois’ Lupus Erythematosus, Ed.7th, Wallace DJ, Hahn BH (eds.). Lippincot Williams & Wilkins, Philadelphia 2007; 1058-1080. .
10.
Clancy RM, Marion MC, Kaufman KM, et al. Identification of candidate loci at 6p21 and 21q22 in a genome-wide association study of cardiac manifestations of neonatal lupus. Arthritis Rheum 2010; 62: 3415-3424. .
11.
Karnabi E, Boutjdir M. Role of Calcium channel In CHB. Scan J Immunol 2010; 72: 226-234. .
12.
Friedman DM, Kim MY, Copel JA, et al. Utility of Cardiac Monitoring in Fetuses at Risk for Congenital Heart Block. The PR Interval and Dexamethasone Evaluation (PRIDE) Prospective Study. Circulation 2008; 117: 485-493. .
13.
Jaeggi ET, Silverman ED, Laskin C, et al. Prolongation of the Atrioventricular Conduction in Fetuses Exposed to Maternal Anti-Ro/SSA and Anti-La/SSB Antibodies Did Not Predict Progressive Heart Block. A Prospective Observational Study on the Effects of Maternal Antibodies on 165 Fetuses. J Am Coll Cardiol 2011; 57: 1487-1492. .
14.
Friedman DM, Kim MY, Copel JA, et al. Prospective evaluation of fetuses with autoimmune associated Congenital Heart Block followed in the the PR Interval and Dexamethasone Evaluation (PRIDE) Study. Am J Cardiol 2009; 103: 1102-1106. .
15.
Hornberger LK, Rajaa NA. Spectrum of cardiac involvement in neonatal lupus. Scand J Immunol 2010; 72: 189-197. .
16.
Nield LE, Silverman ED, Smallhorn JF, et al. Endocardial Fibroelastosis associated with Maternal Anti-Ro and Anti-La Antibodies in the absence of atrioventricular block. J Am Coll Cardiol 2002; 40: 796-802. .
17.
Nield LE, Silverman ED, Taylor GP et al. Maternal Anti-Ro and Anti-La Antibody-Associated Endocardial Fibroelastosis. Circulation 2002; 105: 843-848. .
18.
Moak JP, Barron KS, Hougen TJ, et al. Congenital heart block: development of late-onset cardiomyopathy, a previously underappreciated sequel. J Am Coll Cardiol 2001; 37: 238-242. .
19.
Brucato A, Frassi M, Franceschini F, et al. Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women. Arthritis Rheum 2001; 44: 1832-1835. .
20.
Cimaz R, Spence DL, Hornberger L, et al. Incidence and spectrum of neonatal lupus erythematosus: a prospective study of infants born to mothers with anti-Ro autoantibodies. J Pediatr 2003; 142: 678-683. .
21.
Llanos C, Izmirly PM, Katholi M, et al. Reccurence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors. Arthritis Rheum 2009; 60: 3091-3097. .
22.
Izmirly PM, Llanos C, Lee LL, et al. Cutaneous manifestations of neonatal lupus and risk for subsequent congenital heart block. Arthritis Rheum 2010; 62: 1153-1157. .
23.
Izmirly PM, Kim MY, Llanos C, et al. Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann Rheum Dis 2010; 68: 1827-1830. .
24.
Jaeggi E, Laskin C, Hamilton R, et al. The importance of the level of maternal anti-Ro/SSA antibodies as a prognostic marker of the development of cardiac neonatal lupus erythematosus a prospective study of 186 antibody-exposed fetuses and infants. J Am Coll Cardiol 2010; 55: 2778-2784. .
25.
Defendenti C, Atzeni F, Spina MF, et al. Clinical and laboratory aspects of Ro/SSA-52 autoantibodies. Autoimmunity Rev 2011; 10: 150-154. .
26.
Strandberg L, Winqvist O, Sonesson SE, et al. Antibodies to amino acid 200-239 (p200) of Ro52 as serological markers for the risk of developing congenital heart block. Clin Exp Immunol 2008; 154: 30-37. .
27.
Tzioufas A, Routsias J. Idiotype, antiidiotype network of antibodies. Pathogenetic considerations and clinical applications. Autoimmunity Rev 2010; 9: 631-633. .
28.
Spence DL, Hornberger L, Hamilton R, et al. Increased risk of complete congenital heart block in infants born to woman with hypothyroidism and anti-Ro and/or anti-La antibodies. J Rheumatol 2006; 33: 167-170. .
29.
Askanaze AD, Izmirly PM, Katholi M, et al. Frequency of neuro-psychiatric dysfunction in anti-SSA/SSB exposed children with and without neonatal lupus. Lupus 2010; 19: 300-306. .
30.
Silverman E, Jaeggi E. Non-cardiac manifestations of NLE. Scan J Immunol 2010; 72: 223-225. .
31.
Buyon JP, Clancy RM, Friedman DM. Cardiac manifestations of neonatal lupus erythematosus: guidelines to management, integrating clues from the bench and bedside. Nature Clin Pract 2009; 3: 139-148. .
32.
Hutter D, Silverman ED, Jaeggi E. The benefits of transplacental treatment of isolated congenital CHB associated with maternal anti-Ro/SSA antibodies: a review. Scan J Immuol 2010; 72: 235-241. .
33.
Friedman DM, Llanos C, Izmirly PM, et al. Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open-label clinical trial. Arthritis Rheum 2010; 62: 1138-1146 .
34.
Hansen RJ, Balthasar JP. Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. Thromb Haemost 2002; 88: 898-899. .
35.
Ni H, Chen P, Spring CM, et al. A novel murine model of fetal and neonatal alloimmune thrombocytopenia: response to intravenous IgG therapy. Blood 2006; 107: 2976-2983. .
36.
Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 291: 484-486. .
37.
Pisoni CN, Brucato A, Ruffatti A, et al. Failure of intravenous immunoglobulin to prevent congenital heart block: Findings of a multicenter, prospective, observational study. Arthritis Rheum 2010; 62: 1147-1152. .
38.
Ostensen M. Intravenous immunoglobulin does not prevent recurrence of CHB in children of SSA/Ro positive mothers. Arthritis Rheum 2010; 62: 911-914.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
